ESEdward Z. Song

Edward Z. Song

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Edward Z. Song has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Viral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor

    by Qian Zhang, Yihao Wu, Jingyi Yang, Kevin Zhou, Eric Nigel Ebenezer Anand Manoharan, Tyra Wentz, Leon Su, Alvin Yu, Hong-Yi Wang, Laurakay Bruhn, et al.

  • Open Access

    Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma

    by Edward Z. Song, Andrea Timpanaro, Michael Meechan, Leonel Elena-Sanchez, Lucy Z. Li, Sophie Jamet, Davina S. Lau, Lily I. Winter, Matthew D. Dun, Jessica B. Foster, et al.

    Diffuse intrinsic pontine glioma (DIPG) is a fatal brainstem tumor desperately in need of better treatments. Chimeric antigen receptor (CAR) T cell therapies for DIPG have demonstrated clinical tolerability and bioactivity, but not universal benefit. A major obstacle is insufficient CAR T cell trafficking to the tumor. As our recent clinical trials have demonstrated locoregional elevation of CXCL10, a ligand of the chemokine receptor CXCR3, here we aim to leverage this CXCL10 upregulation to enhance cell trafficking by engineering our B7-H3-targeting CAR T cells to overexpress CXCR3 variants. We demonstrate that, compared to unmodified B7-H3 CAR T cells, CXCR3-A-modified CAR T cells migrate more efficiently toward CXCR3 ligands in vitro, and when delivered intracerebroventricularly in orthotopic DIPG mouse models, CXCR3-A-modified CAR T cells show enhanced trafficking into the tumor and improved therapeutic efficacy. Overall, our data support the potential for engineering CXCR3-A expression to enhance CAR T cell trafficking and efficacy against DIPG.


  • Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors

    by Andrea Timpanaro, Edward Z. Song, Nour Amwas, Chu-Hsuan Chiu, Rebecca Ronsley, Mallory R. Taylor, Jessica B. Foster, Leo D. Wang, Nicholas A. Vitanza

    Central nervous system (CNS) tumors are a leading cause of pediatric cancer-related death. Chimeric antigen receptor (CAR) T cells are an innovative approach for these affected children who are in desperate need of novel therapies, but CNS-directed cellular therapies have only recently advanced to the clinic. Although early-phase trials have begun to demonstrate the feasibility of manufacturing fractionated doses and the tolerability of repeated infusions for children with CNS tumors, major challenges remain. In this review, we will take an inventory of the current state of the pediatric CNS CAR T-cell field through the lens of translational obstacles to broader clinical success. Significance: CNS tumors are the leading cause of cancer-related death in children, highlighting the dire need for new treatment strategies. CAR T cells represent a unique approach, distinct from the cytotoxic chemotherapies and small-molecule inhibitors that have dominated the clinical trial space for decades. Phase I CAR T-cell trials have shown feasibility and possible efficacy against pediatric CNS tumors; however, many challenges must be overcome if these therapeutics are going to be beneficial to most affected children. Although rapid translational development and early-phase trials have quickly evolved our understanding, the pediatric CNS CAR T-cell community now yearns for critical assessments and open dialogue about overcoming the remaining obstacles ahead.


  • Open Access

    Engineered CXCR3-A expression enhances the trafficking and efficacy of intracerebroventricularly delivered B7-H3-targeting CAR T cells against diffuse intrinsic pontine glioma

    by Nicholas Vitanza, Edward Song, Andrea Timpanaro, Michael Meechan, Leonel Sanchez, Lucy Li, Sophie Jamet, Davina Lau, Lily Winter, Matthew Dun, et al.

    Diffuse intrinsic pontine glioma (DIPG) is a fatal brainstem tumor desperately in need of better treatments. CAR T cell therapies for DIPG have demonstrated clinical tolerability and bioactivity, but not universal benefit. A major obstacle is insufficient CAR T cell trafficking to the tumor. As our clinical trials have demonstrated locoregional elevation of CXCL10, a ligand of the chemokine receptor CXCR3, we aimed to leverage this CXCL10 to enhance cell trafficking by engineering our B7-H3-targeting CAR T cells to overexpress CXCR3 variants. Here, we demonstrate that, compared to unmodified B7-H3 CAR T cells, CXCR3-A-modified CAR T cells migrate more efficiently toward CXCR3 ligands in vitro, and when delivered intracerebroventricularly in orthotopic DIPG mouse models, CXCR3-A-modified CAR T cells show enhanced trafficking into the tumor and improved therapeutic efficacy. Overall, our data support the potential for engineering CXCR3-A expression to enhance CAR T cell trafficking and efficacy against DIPG.

  • Open Access

    Enhancing CAR T function with the engineered secretion of C. perfringens neuraminidase

    by Joseph S. Durgin, Radhika Thokala, Lexus Johnson, Edward Song, John Leferovich, Vijay Bhoj, Saba Ghassemi, Michael Milone, Zev Binder, Donald M. O'ROurke, et al.